arrow
M

Milena Gianfrancesco

Pfizer Inc
H指数:33
被引数:7,308

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Risk of serious infection, myocardial infarction, stroke, and thromboembolic events in patients in the United States with ulcerative colitis treated with tofacitinib compared with biologic treatments

与生物制剂治疗相比,美国溃疡性结肠炎患者使用托法替布治疗发生严重感染、心肌梗死、中风和血栓栓塞事件的风险

2026-07-280
OAAI
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States

与生物制剂治疗相比,托法替尼治疗银屑病关节炎患者发生严重感染、心肌梗死或卒中、静脉血栓栓塞事件及恶性肿瘤的风险。

2026-03-250
OAAI
The MI-CLAIM-GEN checklist for generative artificial intelligence in health

健康领域生成式人工智能的MI-CLAIM-GEN检查清单

2025-02-060
PRE
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry

风险因素对未接种疫苗的风湿性疾病患者新型冠状病毒肺炎结局的影响: 使用新型冠状病毒肺炎全球风湿病联盟注册表对大流行时期的比较分析

2023-11-075
OA
Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

种族/民族与美国系统性红斑狼疮患者新型冠状病毒肺炎结局之间的关系: 来自新型冠状病毒肺炎全球风湿病学联盟的数据

2022-12-0212
OA
Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

环境和社会因素与风湿性疾病患者COVID-19-related死亡相关: 一项观察性研究

2022-09-0111
OAAI